Devang Lodhavia, MD
Nephrology · Voorhees, NJNPI 1679570634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Vifor Pharma, Inc. at 32.9% of the total.
Across 59 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$568
- Ardelyx, Inc.$300
- Boehringer Ingelheim$165
- ANI Pharmaceuticals, Inc.$116
- AstraZeneca$106
- Amgen$96
- plus $375 from 11 others
Across 2 payments — averaging $159,622 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$319K
What the payments were for
- Food & beverage$1,68498%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 9 | $568 |
| Ardelyx, Inc. | 8 | $300 |
| Boehringer Ingelheim | 4 | $165 |
| ANI Pharmaceuticals, Inc. | 6 | $116 |
| AstraZeneca | 7 | $106 |
| Amgen | 6 | $96 |
| Akebia Therapeutics Inc | 4 | $79 |
| Shield Therapeutics Inc | 1 | $44 |
| Baxter Healthcare | 1 | $42 |
| Travere Therapeutics, Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Calliditas Therapeutics US Inc. | 2 | $28 |
| GSK | 2 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$345
- XPHOZAH 30 MG$234
- JARDIANCE$125
How this compares
$1,726 in reported general payments places this provider in the 60th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 162 | $177,935 |
| JardianceEmpagliflozin | 53 | $64,235 |
| VeltassaPatiromer Calcium Sorbitex | 38 | $55,707 |
| VelphoroSucroferric Oxyhydroxide | 13 | $26,604 |
| KerendiaFinerenone | 21 | $25,915 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $18,186 |
| TradjentaLinagliptin | 17 | $12,162 |
| Clonidine | 68 | $9,315 |
| Cinacalcet Hcl | 35 | $8,180 |
| Sevelamer Carbonate | 91 | $6,286 |
| JanuviaSitagliptin Phosphate | 11 | $6,200 |
| ProcritEpoetin Alfa | 11 | $5,783 |
| Allopurinol | 127 | $4,846 |
| SteglatroErtugliflozin Pidolate | 11 | $4,476 |
| Losartan Potassium | 330 | $3,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $106 | $196,122183 claims |
| Boehringer IngelheimJardiance, Tradjenta | $165 | $76,39770 claims |
| Fresenius USA Marketing, Inc.Velphoro | $18 | $26,60413 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $116 | $1,09842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Voorhees
- Carmen Canals-NavasVoorhees$12K
- Nitesh PatelVoorhees$11K
- Gopika BankerVoorhees$11K
- Anthony BrownVoorhees$8K
- Gerardo VaralloVoorhees$8K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.